Zhejiang East Asia Pharmaceutical Co Ltd

Zhejiang East Asia Pharmaceutical Co Ltd has a market price of 20.92 CNY and a market cap of 2.4 billion CNY, with a price-to-book ratio of 1.33 and a price-to-tangible-book ratio of 1.33. The company's enterprise value to EBITDA is negative at -40.12, and its enterprise value to revenue is 3.61, indicating a challenging valuation environment. The company's profitability is underperforming, with a return on equity of -4.56% and a return on assets of -2.47%. These metrics fall below the typical expectations for the Pharmaceuticals industry, which emphasizes high returns on invested capital and strong gross margins. The operating loss of 84.6 million CNY and net loss of 82.4 million CNY further highlight the company's current financial distress. The company's revenue is concentrated in its domestic market, with no disclosed breakdown of international sales. The lack of geographic diversification increases exposure to local economic and regulatory risks. The company's product portfolio is focused on antibacterial, anticholinergic, and antifungal drugs, with no disclosed segmental revenue breakdown. The company's growth trajectory is negative, with a net loss and declining cash flows. The operating cash flow is -268.9 million CNY, and free cash flow is -9.98 million CNY, indicating a lack of liquidity generation. The capital expenditure of -74.3 million CNY suggests ongoing investment, but the negative cash flows suggest that the company is not generating sufficient internal cash to fund these activities. The company faces medium liquidity risk, with a current ratio of 1.73 and a debt-to-equity ratio of 0.55. The negative net cash position after subtracting total debt is a key flag. The dilution risk is low, with no near-term pressure indicated by the shares outstanding data. Recent events include the company's latest financial filing, which discloses the operating and net losses. No recent transcripts or significant regulatory filings have been identified that would alter the current risk profile.